Nefecon

Not so fast: FDA tacks 3 more months onto decision date for Calliditas' rare kidney disorder drug
Endpoints
Wed, 09/15/21 - 10:09 pm
Calliditas
FDA
Nefecon
kidney disease
Several months after rebranding, an old Martin Skhreli company touts promising pivotal data in a rare kidney disorder
Endpoints
Mon, 08/16/21 - 12:12 pm
Calliditas
Martin Shkreli
Nefecon
Travere Therapeutics
FDA sets September review date for Calliditas’ rare kidney disease drug
Pharmaforum
Thu, 04/29/21 - 10:26 am
Calliditas
Nefecon
primary IgA nephropathy
kidney disease
FDA
With industry's growing kidney moment, Everest begins building kidney portfolio
BioCentury
Mon, 06/10/19 - 09:29 am
Everest Medicines
Calliditas
Nefecon
clinical trials
IgA nephropathy
kidney disease